The Effect of a Charcoal Deactivation Pouch on Opioid Disposal After Cesarean Delivery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05498025

Enrollment

Registered

2022-08-11

Start date

2023-02-21

Completion date

2023-07-29

Last updated

2024-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications, Obstetric Pain, Opioid Misuse, Pain, Acute

Keywords

opioid disposal, drug deactivation, Deterra

Brief summary

Background: There is scarce literature investigating how patients dispose of unused opioid supplies after their cesarean postoperative pain has faded. The Office of the Surgeon General has identified research on the prevention of opioid use disorder area as well as research on the management of pain as a Surgeon General Priority that needs urgent investigation. Hypothesis: At least 33% of postpartum women discharged home with an opioid prescription and a drug deactivation pouch will use the pouch to dispose of remaining opioids within 30 days of delivery. Methods: This is a prospective single arm interventional pilot study.

Interventions

OTHERDeterra activated charcoal pouch

drug disposal pouch

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

This is a prospective single arm interventional pilot study.

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18+ at time of enrollment, per ERM * Delivered ≥26.0 weeks, per ERM * Status post low transverse cesarean delivery, per ERM * Physically located on labor & delivery and is postpartum day #1 or #2 at time of enrollment, per ERM * Opioid prescription has been sent (per ERM) or will be sent (per obstetric team).

Exclusion criteria

* Positive urine toxicology anytime in pregnancy for non-prescription opioids, fentanyl, amphetamines, benzodiazepines, cannabinoids, LSD, or cocaine, per ERM. * Buprenorphine or methadone Rx, per ERM * Patient preferred communication language not English, per ERM * Documented history, per ERM: * Cannabinoid use disorder * Hypnotic use disorder * Opioid use disorder * Stimulant use disorder * Fibromyalgia * Sickle cell anemia * Lumbar disc herniation * Multiple sclerosis * Trigeminal neuralgia * Active cancer * Complex regional pain syndrome * Systemic lupus erythematosus * Rheumatoid arthritis

Design outcomes

Primary

Measure	Time frame	Description
Actual pouch use	30 days	The percentage of women who used the pouch to dispose of opioids in the home 30 days after delivery (%)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026